Industry News

Zydus Lifesciences Limited has completed the acquisition of biologics manufacturing facilities from U.S.-based Agenus Inc., marking a major step in its global biologics and contract development and manufacturing (CDMO) strategy. Following regulatory clearances, including approval from the Committee on Foreign Investment in the United States (CFIUS), the acquired assets will operate under a newly formed U.S. subsidiary, Zylidac Bio LLC.

Sentynl Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZYCUBO® (copper histidinate) for the treatment of patients with Menkes disease, a rare, inherited disorder that affects copper absorption and distribution in the body.

Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the United States, following approval from the U.S. Food and Drug Administration (USFDA). The product is the generic equivalent of Extra-Strength Pataday® (of Novartis AG) Once-Daily Relief, a leading over-the-counter antihistamine eye drop.

Novo Nordisk has received a significant legal victory in China’s Supreme People’s Court, which affirmed the validity of the company’s semaglutide compound patent, strengthening intellectual property protections for one of its most important medicines.